

WuXi's API manufacturing passes FDA inspection

19 August 2014 | Regulatory | By BioSpectrum Bureau



Singapore: China-based WuXiPharmaTech, pharmaceutical, biotechnology and medical device research and development outsourcing company, has successfully passed the US Food and Drug Administration (FDA) inspection for its Shanghai SynTheAll Pharmaceutical subsidiary for the manufacturing unit of active pharmaceutical ingredient (API) for a branded commercial drug.

"We are very pleased to have passed a second FDA inspection of our manufacturing facilities," said Dr Ge Li, chairman and CEO of WuXiPharmaTech. "These favorable outcomes reflect our dedication to maintaining the highest quality standards throughout our organization."